



Figure 7-1 : The upper row shows immunostaining findings of SFT tissue before Pazopanib treatment, the middle row after Pazopanib treatment, and the lower row after Nivolumab treatment.

	p53	Ki67	PD-1	PD-L1	PD-L2	VEGF	CD4	CD8	Her2	EGFR
Before Pazopanib	-	+	+	+	+	+	+	+	-	+
After Pazopanib	-	+	+	-	-	+	+	+	+	+
After Nivolumab	-	+	+	+	-	+	-	+	-	+

Figure 7-2 : The positive and negative immunostaining findings during the course were tabulated. Ki-67, PD-1, VEGF, CD8, and EGFR were all positive, but p53 was all negative. PD-L2 was positive before treatment with Pazopanib, but became negative thereafter. PD-L1 became negative once after treatment with Pazopanib, but became positive after administration of Nivolumab. CD4 was positive until after Pazopanib administration, but then became negative. Her2 was positive only after administration of Pazopanib.